CTLA-4 Regulates Tolerance Induction and T Cell Differentiation In Vivo

Theresa L. Walunas and Jeffrey A. Bluestone
J Immunol April 15, 1998, 160 (8) 3855-3860;

Abstract

Cytotoxic T lymphocyte Ag-4 (CTLA-4; CD152) is an important T cell regulatory molecule. In vitro experiments have shown that the blockade of signals through CTLA-4 augments T cell expansion, while CTLA-4 cross-linking results in decreased T cell proliferation due to decreased IL-2 production. However, less is known about the role of CTLA-4 in regulating an ongoing immune response. In this study, we examined the role of CTLA-4 in the expansion, decline, tolerization, and differentiation of T cells following treatment with staphylococcal enterotoxin B (SEB). Anti-CTLA-4 treatment resulted in increased numbers of SEB-reactive T cells and blockade of subsequent tolerance induction. Further examination of the SEB-reactive cells from anti-CTLA-4-treated mice demonstrated that both the CD4+ and CD8+ Vβ8+ T cells produced IL-4, providing evidence that not only do signals through CTLA-4 regulate T cell-tolerizing events, but they also play an important role in the differentiation of T cells in vivo.

CTLA-4 (CD152) is a glycoprotein that is primarily expressed on the surface of activated T cells and shares with CD28 the ability to ligate the B7 family molecules B7-1 (CD80) and B7-2 (CD86; 1 . Current evidence suggests that cross-linking of CTLA-4 has a negative regulatory effect on T cells by down-regulating IL-2 production, cell cycle progression, and anti-CD3-induced cyclins (2, 3, 4). Thus, blockade of CTLA-4 signals prolongs T cell activation and expansion both in vitro (5) and in vivo (6, 7). Several additional lines of evidence now exist that suggest that CTLA-4 plays a role in regulating peripheral T cell tolerance and differentiation. First, CTLA-4-deficient mice develop a lymphoproliferative disorder and develop severe autoimmune disease that results in death approximately 3 wk after birth. When restimulated in vitro, T cells from these mice secrete high levels of IL-4 and IFN-γ, consistent with a role for CTLA-4 in the regulation of T cell differentiation (8, 9). In addition, anti-CTLA-4 treatment exacerbates autoimmune disease in a murine model of multiple sclerosis (10). Finally, administration of anti-CTLA-4 mAb to mice concurrently with a tolerizing Ag regimen resulted in the appearance of Ag-reactive T cells (11). Thus, CTLA-4 is likely to play a critical role in the regulation of many aspects of the immune response.

While the systems described above have provided insights into the individual aspects of the immune response, we were interested in examining the role of CTLA-4 throughout the course of an Ag-stimulated immune response. Superantigen administration to mice has been an effective model system in which to study the expansion, decline, and tolerization of Ag-specific T cells. Treatment of mice with staphylococcal enterotoxin B (SEB)3 results in an initial expansion of Vβ8+ T cells that peaks 2 to 3 days following injection. This profound clonal expansion is followed by a precipitous Fas/TNF-regulated (12, 13, 14) decline in the number of Vβ8+ cells (15). The small number of remaining CD4+Vβ8+ T cells are unresponsive to in vitro challenge with SEB or anti-Vβ8 mAb as assessed by proliferation and IL-2 production (16, 17). Treatment with whole or Fab fragments of anti-CTLA-4 mAb has been shown to augment the “early” expansion of SEB-reactive T cells (7). However, the role of CTLA-4 in the ultimate outcome of SEB administration, the clonal inactivation of SEB-reactive cells, and the differentiation of these T cells was not addressed.

In this investigation, we directly examined the role of CTLA-4 in the regulation of the superantigen response by studying the effects of anti-CTLA-4 treatment on the early and late stages of SEB-mediated T cell expansion, contraction, inactivation, and differentiation. The results demonstrate that anti-CTLA-4 administration not only results in increased numbers of SEB-reactive T cells in vivo, but enables the SEB-reactive T cells to retain their ability to proliferate and secrete IL-2 when rechallenged with SEB in vitro. Moreover, blockade of CTLA-4 during SEB-mediated Vβ8+ activation promoted the differentiation of both CD4+ and CD8+Vβ8+ T cell subsets into IL-4-producing T cells. These results support a critical role for CTLA-4 engagement in the regulation of both tolerance induction and T cell differentiation in vivo.

Materials and Methods

Animals

Female BALB/c mice (4–8 wk old) were purchased from Frederick National Cancer Research Institute (Bethesda, MD) and maintained under specific pathogen-free conditions in the University of Chicago Animal Barrier Facility.

Cell lines and reagents

UC10-4F10-11 (4F10) (hamster anti-murine CTLA-4) was produced in an Acucyst Jr. bioreactor (Cellex Biosciences, Minneapolis, MN). The high-titered supernatant was purified over protein A-Sepharose and tested for purity, absence of endotoxin, and functionality as previously described (5). RL172.4 (anti-murine CD4; 18 ascites and 3.155 (rat anti-murine CD8; 19 and 2.4G2 (rat anti-murine FcR; 20 culture supernatants were prepared in our laboratory. Affinity-purified hamster IgG was purchased from Cappel Research Products (Durham, NC) and was used as a negative control (Ct Ig) for 4F10. FITC-conjugated anti-CD8 (YTS 169.42; 21 and rat anti-murine CD4 (GK1.5; 22 were prepared in our laboratory. FITC-conjugated 145-2C11 (hamster anti-murine CD3ε) was provided by Boehringer Mannheim (Indianapolis, IN). Biotin-conjugated anti-Vβ8.1/Vβ8.2 (MR5-2) and phycoerythrin-conjugated anti-Vβ10 (B21.5) were purchased from PharMingen (San Diego, CA). Phycoerythrin-conjugated streptavidin was purchased from Southern Biotechnology Associates (Birmingham, AL). SEB was purchased from Sigma Chemical (St. Louis, MO).

In vivo treatment with SEB

BALB/c mice were treated i.p. with PBS or 100 μg of SEB on day 0. Each day for the next 7 days, animals were treated i.p. with either PBS, 100 μg of Ct Ig, or 100 μg of anti-CTLA-4 mAb as indicated. At the end of treatment, animals were sacrificed and spleen cell suspensions were prepared and analyzed. Splenocytes were depleted of erythrocytes by hypotonic lysis.

Flow cytometry

The number of CD4+ and CD8+ cells expressing the SEB-reactive Vβ8+ TCR and SEB-nonreactive Vβ10+ TCR was determined by two-color flow cytometric analysis. Following harvest, cells were washed once in FACS buffer (1.0% BSA and 0.01% sodium azide in PBS, pH 7.4), incubated with 20 μl 2.4G2 culture supernatant, and simultaneously stained for 30 min at 4°C with FITC-, phycoerythrin- or biotin-conjugated mAb. Cells were then washed in FACS buffer and incubated with phycoerythrin-conjugated streptavidin for 15 min at room temperature. After a final wash, cells were resuspended in FACS buffer and analyzed on a FACscan flow cytometer (Becton Dickinson, Mountain View, CA). Incorporation of propidium iodide was used to exclude dead cells. Data from 104 live cells were analyzed using Lysis II software (Becton Dickinson).

Depletion of CD4+ and CD8+ T cells

In each experiment, equal numbers of splenocytes from three SEB-treated and three SEB and anti-CTLA-4-treated mice were individually pooled. Pooled splenocytes were incubated at 2 × 107 cells/ml with a 1:1000 dilution of anti-CD4 (RL172.4) ascites or a 1:4 dilution of anti-CD8 (3.155) culture supernatant for 30 min at 4°C. An equal volume of rabbit complement (Pel-Freez, Brown Deer, WI), diluted 1:10 in 4°C PBS, was added to the cells, and the cells were incubated at 37°C for 45 min with constant mixing. Cells were passed over Ficoll-Hypaque to eliminate dead cells. Efficiency of depletion was determined by flow cytometry to be greater than 95%.

Restimulation of SEB-treated cells in vitro

Splenocyte suspensions were normalized for CD3+ or Vβ8+ T cell numbers (as described in Results) and plated at 2 × 105 CD3+ T cells/well or 2.5 × 104 Vβ8+ T cells/well in 96-well round-bottom plates. Cells were cultured with 1 μg/ml SEB, 10 μg/ml SEB, or medium alone (DMEM containing 10% FCS). Supernatants were collected at 24 h to determine IL-2 production and at 48 h to determine IFN-γ and IL-4 production. Cells were harvested at approximately 64 h after culture initiation following a 16-h pulse with 1 μCi/well of [3H]thymidine (Amersham, Arlington Heights, IL) to assess proliferation. Data points are represented as the mean of triplicate wells. SEs were less than 20%.

Analysis of cytokine production

Cytokine-containing supernatants were stored at −20°C until analyzed. IL-2 and IL-4 were determined using commercial ELISA kits from Endogen (Cambridge, MA). IFN-γ was determined using an ELISA assay, and reagents were developed and kindly provided by Dr. Robert Schreiber (Washington University, St. Louis, MO). Recombinant murine IL-2, IL-4, and IFN-γ standards were used to quantify cytokine levels in the supernatants.

Results

Anti-CTLA-4 augments expansion of SEB-reactive T cells in vivo

Treatment of mice with SEB results in expansion of Vβ8+ T cells. This expansion peaks at 2 to 3 days followed by a precipitous decline in the numbers of SEB-reactive cells (15). Seven days after treatment, the numbers of CD4+Vβ8+ T cells are often below the levels observed before superantigen treatment (23). As seen in Figure 1⇓, the administration of anti-CTLA-4 mAbs, concomitant with injection of SEB, resulted in increased numbers of Vβ8+ T cells compared with that observed in control-treated animals. The increase of Vβ8+ T cells occurs in both the CD4+ (Fig. 1⇓) and CD8+ (data not shown) T cell subsets. Vβ8+ T cell expansion requires antigenic challenge, as anti-CTLA-4 treatment in the absence of SEB treatment did not result in an observable increase in Vβ8+ T cell number (Fig. 1⇓). The effect of anti-CTLA-4 mAbs is specific to SEB-reactive T cell populations, since the absolute numbers of SEB-nonreactive Vβ10+ T cells did not change significantly following superantigen treatment in either the absence or the presence of anti-CTLA-4 mAb. These results are similar to those of previous studies demonstrating that whole or Fab fragments of anti-CTLA-4 can augment expansion of Ag-reactive (6) and superantigen-reactive (7) T cells. Thus, taken together, these data suggest that blockade of signals through CTLA-4 during a response to SEB blocks a negative signal to activated T cells, resulting in an increase in the number of Ag-reactive T cells.

FIGURE 1.
FIGURE 1.

Blockade of CTLA-4 during an SEB-mediated immune response increases the numbers of superantigen-reactive T cells. Mice were immunized with either 100 μl PBS or 100 μg SEB on day 0. To evaluate the effects of blockade of CTLA-4, mice in both of these groups were then treated under control conditions (PBS or Ct Ig) or with anti-CTLA-4 with 100 μg/mouse daily for 7 days. CD4+ T cells were analyzed by two-color flow cytometry for the number of SEB-reactive Vβ8+ T cells (closed bars) and non-SEB-reactive Vβ10+ T cells (open bars). Results are represented as the absolute number of the indicated T cells/spleen, and the SE of the mean is indicated. All groups are representative of four mice, except the group treated with both SEB and anti-CTLA-4, which is representative of six mice.

Blockade of CTLA-4 inhibits tolerance induction by SEB

Previous studies have shown that following in vivo treatment with SEB, the residual CD4+Vβ8+ T cells are hyporesponsive to restimulation with SEB in vitro (16, 17). Figure 2⇓ depicts the in vitro response (normalized for the number of CD3+ T cells) of bulk T cells following PBS or SEB treatment in the presence of control Ig or anti-CTLA-4 mAb therapy. The results showed comparable proliferative responses of bulk T cells from mice treated with anti-CTLA-4 mAbs at the time of SEB therapy (Fig. 2⇓, bottom). Similar results were observed when whole splenocytes were normalized for Vβ8+ T cells and restimulated with SEB in vitro (Fig. 3⇓, top). It has previously been demonstrated that Vβ8+CD8+ T cells do not become hyporesponsive subsequent to SEB treatment and retain the ability to proliferate and produce IFN-γ when restimulated with SEB (24). Thus, it was possible that low levels of IL-2 produced by the CD4+ T cells in the control SEB cultures along with SEB stimulation was enough to promote the proliferation of the SEB-reactive CD8+ T cells. Consistent with this hypothesis, very little proliferation by the SEB-reactive CD8+ T cells was observed in the absence of CD4+ T cells. However, these cells did produce IFN-γ at levels comparable with that observed from the T cells from control SEB-treated animals, suggesting that they were not unresponsive to restimulation with SEB (data not shown). By comparison, depletion of CD8+ T cells resulted in an increased proliferative response by T cells from mice treated with both SEB and anti-CTLA-4, as compared with T cells from control SEB-treated mice (Fig. 3⇓, bottom). Thus, the CD8+ T cells may consume the increased IL-2 produced by splenic T cells from mice treated with both anti-CTLA-4 mAb and SEB but proliferate less well due to the less effective interaction of SEB with CD8+ T cells, thus reducing the incorporation of [3H]thymidine in the culture (Fig. 2⇓, top). These data suggest that the SEB-reactive CD4+Vβ8+ T cells were more responsive to Ag following anti-CTLA-4 treatment.

FIGURE 2.
FIGURE 2.

Blockade of CTLA-4 during an SEB-mediated immune response promotes IL-2 production by SEB-reactive T cells. Mice were treated as described in the legend to Figure 1⇑. Splenic cells were normalized for CD3+ cell number (2 × 105 T cells/well), and samples from individual animals were analyzed for IL-2 production (top) and proliferation (bottom) in response to SEB. To analyze proliferation, cells were stimulated for 72 h with medium or 1 μg/ml SEB, and proliferation in medium alone was subtracted from that of SEB-stimulated proliferation. IL-2 was analyzed 24 h after initiation of culture conditions. Each symbol represents the proliferative response of an individual animal in a treatment group. The horizontal line represents the mean of the individual samples. Increased IL-2 production by splenic cells from SEB/anti-CTLA-4-treated mice compared with SEB/Ct Ig-treated mice is significant (p < 0.01).

FIGURE 3.
FIGURE 3.

Blockade of CTLA-4 during an SEB-mediated immune response promotes increased proliferation by CD4+Vβ8+ T cells. Mice were treated as described in the legend to Figure 1⇑. Splenic cells were normalized for Vβ8+ T cell number (2.5 × 104 Vβ8+ cells/well), and samples were analyzed for proliferation in response to 1 μg/ml SEB. Top, Bars represent the mean proliferative responses of three individual animals. Bottom, CD8+ T cells were depleted from splenocytes pooled equally from three mice and restimulated with SEB. Bars represent the proliferative response of these cells. Data are representative of two separate experiments.

Blockade of CTLA-4 promotes the differentiation of IFN-γ and IL-4-producing T cells

Blockade of CTLA-4/B7 interactions promoted a significant increase in IL-2 production and proliferative responses by SEB-reactive CD4+ T cells. In previous studies, changes in signaling through CD28 have been shown to have effects on T cell differentiation (25, 26). Thus, it was of interest to determine whether changes in CTLA-4 signaling could also affect T cell differentiation. In Figure 4⇓, splenic T cells from mice stimulated in vivo with either PBS or SEB in the presence of control Ig or anti-CTLA-4 mAb treatment were examined for IL-4 (Fig. 4⇓, left) or IFN-γ (Fig. 4⇓, right) production following restimulation in vitro with SEB. T cells from anti-CTLA-4-treated mice produced significantly more IL-4 when restimulated with SEB, a result that was observed regardless of whether the cells were normalized for CD3+ (Fig. 4⇓) or Vβ8+ T cells (data not shown). In addition, IFN-γ production was also augmented by T cells from the anti-CTLA-4/SEB-treated group. These data suggest that blockade of CTLA-4 signals during a response to SEB promotes both IFN-γ and IL-4 production by SEB-reactive T cells. Interestingly, there was a small, but significant, increase in IL-4 production by T cells from mice treated with anti-CTLA-4 alone. In addition, there was a comparable decrease in IFN-γ production. These results may reflect an effect of CTLA-4 blockade on a small number of Vβ8+ T cells stimulated by endogenous or environmental Ags encountered during the time of treatment with anti-CTLA-4 mAb.

FIGURE 4.
FIGURE 4.

Anti-CTLA-4 treatment during an immune response to SEB results in IL-4-producing SEB-reactive T cells. Mice were treated as described in the legend to Figure 1⇑. Splenic cells were normalized for CD3+ T cell number (2 × 105 T cells/well) and stimulated for 48 h with 10 μg/ml SEB. Samples were then analyzed for IL-4 (left) or IFN-γ (right) by ELISA. Each symbol represents the level of cytokine produced by an individual animal in response to the stimulus. The horizontal line represents the mean of the individual samples. IL-4 produced by PBS- or SEB-treated mice treated with anti-CTLA-4 is significantly increased over that observed from control-treated mice (p < 0.01). IFN-γ produced by SEB/anti-CTLA-4-treated mice is significantly increased over that observed by SEB/Ct Ig-treated mice (p < 0.05).

Enhanced IL-4 production is observed from both CD4+ and CD8+ T cell subsets

The previous results could not distinguish whether anti-CTLA-4 treatment was promoting the expansion of Th0- or both Th1- and Th2-type T cells. In addition, the presence of both CD4+ and CD8+ T cells further complicated the analyses, since studies by other investigators have shown that CD8+ T cells isolated from SEB-treated mice retain their ability to secrete IFN-γ when restimulated with SEB in vitro (24). Therefore, cytokine production by the individual CD4+ and CD8+ T cell subsets was examined to determine the source of IL-4 and IFN-γ. As seen in Figure 5⇓, right, depletion of CD8+ T cells resulted in significantly diminished levels of IFN-γ production by the residual CD4+ T cells in response to SEB. Thus, the majority of the increase in IFN-γ levels can be attributed to the expanded CD8+ T cell subset. In contrast, depletion of CD8+ T cells reduced, but did not eliminate, IL-4 production. These results suggested that CTLA-4 blockade during a response to SEB promoted the differentiation of the CD4+Vβ8+ T cells into IL-4-producing Th2-type T cells. Interestingly, CD8+ T cells isolated from SEB- and control-treated mice produced little, if any, IL-4 (Fig. 4⇑, left). In contrast, at least a small subset of CD8+ T cells from anti-CTLA-4-treated mice were observed to produce IL-4 (Fig. 5⇓, left), suggesting that the blockade of CTLA-4 enhanced IL-4 production by CD8+ T cells as well. However, it remains to be clarified as to whether the IL-4 and IFN-γ are being produced by a cytotoxic T cell (Tc) 0-like population or a mixture of Tc1- and Tc2-like differentiated cells.

FIGURE 5.
FIGURE 5.

IL-4 is produced by SEB-reactive CD4+ and CD8+ T cells. CD4+ and CD8+ T cells from mice treated with SEB and anti-CTLA-4 were examined for the production of IL-4 (left) and IFN-γ (right) following stimulation with SEB. CD4+ (CD8 Depl.) or CD8+ (CD4 Depl.) T cells were depleted from the pooled spleens of three mice using anti-CD4 or anti-CD8 mAb and complement. Cells were normalized for CD3+ T cell number (2 × 105 T cells/well) and stimulated with 10 μg/ml SEB. Production of IL-4 and IFN-γ was evaluated 48 h following stimulation by ELISA. Cytokine production by the bulk pool is determined by averaging the cytokine production of splenic T cells from the individual mice in the pool. Data are representative of two experiments.

Discussion

The regulatory role of CTLA-4 during an immune response is beginning to be understood. Although some studies have suggested a costimulatory role for this molecule (27), our studies, along with several others, have implicated CTLA-4 in the attenuation of T cell expansion. Blockade of CTLA-4/B7 interactions in vitro or in vivo with Abs, or via deletion of the CTLA-4 gene, promotes T cell proliferation and cytokine production (2, 3, 4, 5, 6, 7, 8, 9). In the present studies, we have shown that injection of blocking anti-CTLA-4 mAbs increased the number of surviving T cells in the spleen of SEB-treated mice as compared with mice treated under control conditions. These results are consistent with studies demonstrating enhanced T cell expansion in response to Ag in mice coinjected with anti-CTLA-4 mAbs (6, 7). These studies also show that CTLA-4 engagement blocks proliferation and plays an important role in subsequent inactivation of SEB-exposed T cells. Finally, the data suggest that CTLA-4 ligation inhibits IL-4 production by both CD4+ and CD8+ T cells.

Other investigators have addressed the roles of CD28 and CTLA-4 in the regulation of SEB-induced tolerance. For instance, expression of a soluble form of CTLA-4 (CTLA4Ig) prevents the induction of T cell unresponsiveness following SEB treatment of mice transgenic for CTLA4Ig (28). These results suggested that CTLA4Ig prevents tolerance by disrupting CTLA-4/B7 interactions. However, CTLA4Ig also blocks CD28 engagement, thus preventing the initial activation event that may be required for tolerance induction. The data shown in the present study provide direct evidence that blockade of CTLA-4 prevents T cell anergy in response to SEB, supporting a role for CTLA-4 in SEB-induced unresponsiveness.

It is unclear by what mechanism CTLA-4 regulates peripheral tolerance. It is possible that the blockade of CTLA-4 signals could either prevent the entry of cells into an anergic state or that mAb treatment might reverse an established anergic state. Several results support the possibility that CTLA-4 blockade allows the Vβ8+ T cells to “grow” out of anergy. First, blockade of CTLA-4 signals enhances growth factor production, in particular, IL-2 (10). The addition of exogenous IL-2 has been shown to reverse anergy in Th1 T cell clones in vitro (29), and continuous IL-2 administration during a response to staphylococcal enterotoxin prevents tolerance in the staphylococcal enterotoxin-reactive T cells (30). In addition, blockade of CTLA-4/B7 interactions promotes increased IL-2Rα expression on in vivo SEB-activated T cells 48 h after SEB immunization, and these cells are more IL-2 responsive in vitro compared with cells from control-treated mice (data not shown). Second, previous studies have shown that CTLA-4 blockade can promote cell cycle progression directly, while CTLA-4 cross-linking inhibits the induction of cyclins (4). This results in increased expansion of activated T cells in vitro (2, 3) and may allow the SEB-reactive cells to overcome unresponsiveness in vivo. Finally, CTLA-4 may play a direct role in maintaining Ag-induced tolerance. Previous studies have shown that blockade of CTLA-4 signals can exacerbate autoimmune disease (10), CTLA-4-deficient mice die from an autoimmune disease (8, 9), and anti-CTLA-4 can block tolerization of Ag-specific T cells when Ag is administered under tolerizing conditions (11).

The studies reported here demonstrate an important role for CTLA-4 in T cell differentiation. Both CD4+ and CD8+ T cells from SEB and anti-CTLA-4-treated mice secrete IL-4 when restimulated with SEB. CTLA-4 blockade might promote IL-4 production in several ways. It has been shown, in vitro, that increasing TCR (31) or CD28 (25, 26) signals promotes the development of Th2-like T cells. These data have led to a hypothesis that development of IL-4-producing T cells is dependent on the “strength of signal” delivered to the T cell through the TCR and CD28. Weaker costimulation promotes development of Th1 cells, while stronger stimuli promote the development of Th2 cells (32, 33). Blockade of CTLA-4 signals may increase the strength of signals delivered to the T cell in several ways. First, extracellularly, CTLA-4 may compete with CD28 for the costimulatory ligands B7-1 and B7-2. Treatment with anti-CTLA-4 mAb may block the interaction of CTLA-4 with these ligands, “freeing up” more of these molecules to interact with CD28, increasing the signals through CD28, and thereby promoting IL-4 production. Second, CTLA-4 may compete with CD28 at the intracytoplasmic level. Both CD28 and CTLA-4 have cytoplasmic SH2 domains that can interact with phosphatidyl inositol 3-kinase (34). CTLA-4 signal blockade may provide CD28 with an increased pool of signaling molecules that allow increased signaling through CD28. Finally, CTLA-4 may negatively regulate TCR/CD28 signals directly. CTLA-4 interacts with a tyrosine phosphatase, PTP-1D (35). Translocation of CTLA-4/PTP-1D into the TCR/CD28 complex during an immune response may attenuate signals through the TCR/CD28 by dephosphorylating membrane proximal signaling molecules. Anti-CTLA-4 treatment may prevent CTLA-4 translocation into the TCR/CD28 complex, resulting in increased signaling through these activating components.

Taken together, these studies suggest that CTLA-4 may play an important role in the response to bacterial pathogens where superantigen responses may be a critical component of the immune response. Manipulation of CTLA-4 signals with mAb may provide an important tool for enhancing the host immune response in clinical settings.

Acknowledgments

We thank Ms. Julie Auger and Mr. Paul Butterfield for flow cytometry assistance.

Footnotes

  • ↵1 This research was supported by National Institutes of Health Grants P01 AI35294 and CA14599 and Genetics Institute (Cambridge, MA). T.L.W. was supported by National Institutes of Health Training Grant HL07381-7.

  • ↵2 Address correspondence and reprint requests to Dr. Jeffrey A. Bluestone, 5841 South Maryland Avenue, MC1089, Chicago, IL 60637. E-mail address: jbluest{at}immunology.uchicago.edu

  • 3 Abbreviations used in this paper: SEB, staphylococcal enterotoxin B; Ct Ig, Ig G used as a negative control. Tc, cytotoxic T cell.

  • Received October 14, 1997.
  • Accepted December 22, 1997.

References

  1. ↵
    June, C. H., J. A. Bluestone, L. M. Nadler, C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15: 321
    OpenUrlCrossRefPubMed
  2. ↵
    Walunas, T. L., C. Y. Bakker, J. A. Bluestone. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183: 2541
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Krummel, M. F., J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183: 2533
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Brunner, M., F. Chan, C. Hinkel, J. Hanke, A. Winoto, and J. Allison. 1997. The mechanism of CTLA-4-mediated inhibition of T cell activation [abstract]. In Keystone Symposia: Tolerance and Autoimmunity.
  5. ↵
    Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405
    OpenUrlCrossRefPubMed
  6. ↵
    Kearney, E. R., T. L. Walunas, R. W. Karr, P. A. Morton, D. Y. Loh, J. A. Bluestone, M. K. Jenkins. 1995. Antigen-dependent clonal expansion of a trace population of antigen specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155: 1032
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Krummel, M. F., T. J. Sullivan, J. P. Allison. 1996. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int. Immunol. 8: 519
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541
    OpenUrlCrossRefPubMed
  9. ↵
    Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in ctla-4. Science 270: 985
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, J. A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184: 783
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Perez, V. L., L. Van Parijs, A. Buickians, X. X. Zheng, T. B. Strom, A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6: 411
    OpenUrlCrossRefPubMed
  12. ↵
    Zhou, T., H. Bluethman, J. Zhang, C. K. Edwards, III, J. D. Mountz. 1992. Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice. J. Exp. Med. 176: 1063
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Renno, T., M. Hahne, J. Tcshopp, H. R. MacDonald. 1996. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate fas and fas ligand. J. Exp. Med. 183: 431
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Vella, A. T., J. E. McCormack, P. S. Linsley, J. W. Kappler, P. Marrack. 1995. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2: 261
    OpenUrlCrossRefPubMed
  15. ↵
    Hermann, T., S. Baschieri, R. K. Lees, H. R. MacDonald. 1992. In vivo responses of CD4+ and CD8+ cells to bacterial superantigens. Eur. J. Immunol. 22: 1935
    OpenUrlCrossRefPubMed
  16. ↵
    Rellahan, B. L., L. A. Jones, A. M. Kruisbeek, A. M. Fry, L. A. Matis. 1990. In vivo induction of anergy in peripheral Vβ8+ T cells by staphylococcal enterotoxin B. J. Exp. Med. 172: 1091
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Kawabe, Y., A. Ochi. 1990. Selective anergy of Vβ8+, CD4+ T cells in staphylococcus enterotoxin B-primed mice. J. Exp. Med. 172: 1065
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Ceredig, R., J. W. Lowenthal, M. Nabholz, H. R. MacDonald. 1985. Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature 314: 98
    OpenUrlCrossRefPubMed
  19. ↵
    Sarmiento, M., A. L. Glasebrook, F. W. Fitch. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125: 2665
    OpenUrlAbstract
  20. ↵
    Unkeless, J. C.. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 150: 580
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312: 548
    OpenUrlCrossRefPubMed
  22. ↵
    Dialynas, D. P., Z. S. Quan, K. A. Wall, J. Quintans, M. R. Loken, F. W. Fitch. 1983. Characterization of the murine T cell surface molecule L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu-3/T4 molecule. J. Immunol. 131: 2445
    OpenUrlAbstract/FREE Full Text
  23. ↵
    MacDonald, H. R., S. Baschieri, R. K. Lees. 1991. Clonal expansion precedes anergy and death of Vβ8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur. J. Immunol. 21: 1963
    OpenUrlCrossRefPubMed
  24. ↵
    Baschieri, S., R. K. Lees, A. R. Lussow, H. R. MacDonald. 1993. Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines. Eur. J. Immunol. 23: 2661
    OpenUrlCrossRefPubMed
  25. ↵
    Seder, R. A., R. N. Germain, P. S. Linsley, W. E. Paul. 1994. CD28-mediated co-stimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon γ production. J. Exp. Med. 179: 299
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Rulifson, I. C., A. I. Sperling, P. E. Fields, F. W. Fitch, J. A. Bluestone. 1997. CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 158: 658
    OpenUrlAbstract
  27. ↵
    Wu, Y, Y. Guo, A. Huang, P. Zheng, Y. Liu. 1997. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J. Exp. Med. 185: 1327
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Lane, P., C. Haller, F. McConnell. 1996. Evidence that induction of tolerance in vivo involves active signaling via a B7-ligand dependent mechanism: CTLA-4Ig protects Vβ8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Eur. J. Immunol. 26: 858
    OpenUrlCrossRefPubMed
  29. ↵
    Beverly, B., S. M. Kang, M. J. Lenardo, R. H. Schwartz. 1992. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 4: 661
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Kuroda, K., J. Yagi, K. Imanishi, Z.-J. Yan, X.-Y. Li, W. Fujimaki, H. Kato, T. Miyoshi-Akiyama, Y. Kumazawa, H. Abe, T. Uchiyama. 1996. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen. J. Immunol. 157: 1422
    OpenUrlAbstract
  31. ↵
    Hosken, N. A., K. Shibuya, A. W. Heath, K. M. Murphy, A. O’Garra. 1995. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor αβ-transgenic model. J. Exp. Med. 182: 1579
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Bluestone, J. A.. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2: 555
    OpenUrlCrossRefPubMed
  33. ↵
    Lenschow, D. J., T. L. Walunas, J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233
    OpenUrlCrossRefPubMed
  34. ↵
    Schneider, H., K. V. Prasad, S. E. Shoelson, C. E. Rudd. 1995. CTLA-4 binding to the lipid kinase phosphatidyl inositol 3-kinase in T cells. J. Exp. Med. 181: 351
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Marengere, L. E., P. Waterhouse, G. S. Duncan, H. W. Mittrucker, G. S. Feng, T. W. Mak. 1996. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272: 1170
    OpenUrlAbstract
Back to top

In this issue

The Journal of Immunology
Vol. 160, Issue 8
15 Apr 1998
Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section